<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29614063</article-id><article-id pub-id-type="pmc">5896363</article-id><article-id pub-id-type="doi">10.12659/MSM.906934</article-id><article-id pub-id-type="publisher-id">906934</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qi</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-1970">1</xref><xref ref-type="author-notes" rid="fn1-medscimonit-24-1970">A</xref><xref ref-type="author-notes" rid="fn8-medscimonit-24-1970">*</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Zhaozheng</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-1970">1</xref><xref ref-type="author-notes" rid="fn2-medscimonit-24-1970">B</xref><xref ref-type="author-notes" rid="fn8-medscimonit-24-1970">*</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Qiang</given-names></name><xref ref-type="aff" rid="af2-medscimonit-24-1970">2</xref><xref ref-type="author-notes" rid="fn3-medscimonit-24-1970">C</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-1970">1</xref><xref ref-type="author-notes" rid="fn4-medscimonit-24-1970">D</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-1970">1</xref><xref ref-type="author-notes" rid="fn6-medscimonit-24-1970">F</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Guiyang</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-1970">1</xref><xref ref-type="author-notes" rid="fn5-medscimonit-24-1970">E</xref></contrib></contrib-group><aff id="af1-medscimonit-24-1970">
<label>1</label>Department of Anorectal Surgery, Huzhou Central Hospital, Huzhou, Zhejiang, P.R. China</aff><aff id="af2-medscimonit-24-1970">
<label>2</label>Department of Hepatobiliary Surgery, Huzhou Central Hospital, Huzhou, Zhejiang, P.R. China</aff><author-notes><corresp id="c1-medscimonit-24-1970">Corresponding Author: Guiyang Zhang, e-mail: <email>guiyangzhang@hotmail.com</email></corresp><fn id="fn1-medscimonit-24-1970"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-24-1970"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-24-1970"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-24-1970"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-24-1970"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-24-1970"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-24-1970"><label>G</label><p>Funds Collection</p></fn><fn id="fn8-medscimonit-24-1970"><label>*</label><p>These authors contributed to this work equally</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>03</day><month>4</month><year>2018</year></pub-date><volume>24</volume><fpage>1970</fpage><lpage>1979</lpage><history><date date-type="received"><day>01</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; Med Sci Monit, 2018</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link>)</license-p></license></permissions><abstract><sec><title>Background</title><p>The currently available chemotherapeutic regimens do not use a specifically designed drug delivery system. The objective of this study was to compare outcome measures, adverse effects, and cost of FOLFOX4 and FOLFIRINOX treatments in rectal cancer patients.</p></sec><sec><title>Material/Methods</title><p>We enrolled patients who, after surgery, did not undergo chemotherapy or radiotherapy (Control group); were administered 200 mg/m<sup>2</sup> folinic acid, 400 mg/m<sup>2</sup> fluorouracil, and 85 mg/m<sup>2</sup> oxaliplatin (FFO group); or were administered 400 mg/m<sup>2</sup> folinic acid, 400 mg/m<sup>2</sup> fluorouracil, 180 mg/m<sup>2</sup> irinotecan, and 85 mg/m<sup>2</sup> oxaliplatin (FFIO group). We recorded tumor and nodal staging, carbohydrate antigen 19-9, serum carcinoembryonic antigen, total cost of treatment, disease recurrence, overall survival, and adverse effects. We used the 2-tailed paired <italic>t</italic> test following Turkey post hoc test for adverse effects, recurrence analysis, and cost of treatment at 95% of confidence level.</p></sec><sec><title>Results</title><p>Surgery (<italic>p</italic>=0.00089), FOLFOX4 (<italic>p</italic>=0.000167), and FOLFIRINOX (<italic>p</italic>=0.00013) improved disease-free conditions. Only surgery failed to maintain carbohydrate antigen and carcinoembryonic antigen 19-9 levels. The cost of chemotherapeutic treatments was in the order of FFIO group &#x0003e; FFO group &#x0003e; Control group. Non-fatal treatment-emergent adverse effects were due to chemotherapeutic drugs. However, fatal chemotherapeutic treatment-emergent adverse effects were observed only in the FFIO group. Overall survival, irrespective of cancerous condition, was higher in the FFO group.</p></sec><sec><title>Conclusions</title><p>FOLFIRINOX had less total cancer recurrence than FOLFOX4. However, FOLFIRINOX had more fatal treatment-emergent adverse effects and excessive cost of treatment than FOLFOX4 regimen.</p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Antigens, Tumor-Associated, Carbohydrate</kwd><kwd>Carcinoembryonic Antigen</kwd><kwd>Neoplasm Recurrence, Local</kwd><kwd>Neoplasm Staging</kwd><kwd>Rectal Neoplasms</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>The Central Research Ethics Committee for Oncology Society of China has concluded that rectal cancer is a major fatal condition in PR China. In 2011, there were more than 50 000 new patients with various stages of rectal cancer [<xref rid="b1-medscimonit-24-1970" ref-type="bibr">1</xref>].</p><p>Rectal cancers are found in lymph nodes and rectal walls and are difficult to cure [<xref rid="b2-medscimonit-24-1970" ref-type="bibr">2</xref>]. The current option for treatment is total mesorectal excision or blunt rectal surgical techniques with preoperative or postoperative adjuvant chemotherapy following radiotherapy. Historical studies suggest that adjunct chemotherapy reduces local recurrence [<xref rid="b3-medscimonit-24-1970" ref-type="bibr">3</xref>].</p><p>The current standard chemotherapy in rectal cancer is 5-fluorouracil (5-FU) [<xref rid="b4-medscimonit-24-1970" ref-type="bibr">4</xref>]. Folinic acid (FA) modulates the action of 5-FU and increased survival of patients [<xref rid="b5-medscimonit-24-1970" ref-type="bibr">5</xref>]. Moreover, oxaliplatin (OP) possesses synergistic action with 5-FU and FA [<xref rid="b4-medscimonit-24-1970" ref-type="bibr">4</xref>]. Irinotecan (IT) is a topoisomerase I inhibitor with augmented efficacy with 5-FU in rectal cancer [<xref rid="b6-medscimonit-24-1970" ref-type="bibr">6</xref>].</p><p>There are several regimens used as chemotherapy in rectal cancer, such as FOLFOX (FA, 5-FU, and OP), FOLFIRI (FA, 5-FU, and IT) [<xref rid="b7-medscimonit-24-1970" ref-type="bibr">7</xref>], and FOLFIRINOX (FA, 5-FU, IT, and OP) [<xref rid="b8-medscimonit-24-1970" ref-type="bibr">8</xref>]. There are also 2 regimens for FOLFOX: FOLFOX4 and FOLFOX6. In FOLFOX4, drugs are administered as 12 cycles and cycle/2-weeks [<xref rid="b4-medscimonit-24-1970" ref-type="bibr">4</xref>]. In FOLFOX6, the drugs are administered as 12 cycles and cycle/weeks [<xref rid="b9-medscimonit-24-1970" ref-type="bibr">9</xref>]. These regimens are not targeted, self-engineered, or tailor-made drug delivery systems. They have lethal effects on humans and an increased mortality rate [<xref rid="b10-medscimonit-24-1970" ref-type="bibr">10</xref>]. However, use of chemoradiotherapy after surgery has an effect on local recurrences [<xref rid="b11-medscimonit-24-1970" ref-type="bibr">11</xref>] and overall survival [<xref rid="b12-medscimonit-24-1970" ref-type="bibr">12</xref>] of the patient. Therefore, it is necessary to know the advantages and disadvantages of each chemotherapy regimen.</p><p>The objective of this study was to compare outcome measures, treatment-emergent adverse effects, and cost of treatment of FOLFOX4 and FOLFIRINOX regimens in rectal cancer patients undergoing cancer treatment.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec sec-type="materials"><title>Materials</title><p>Hematoxylin, eosin, normal saline, and formalin were purchased from Wuhan Heng Heda Pharm Co., Ltd. Hubei, China. FA, 5-FU, OP, and IT were purchased from Shandong Sino Pharmaceutical Technology Co., Ltd., Shandong, China, Wuhan Honor Bio-Pharm Co., Ltd., Wuhan, China, Shanghai Yijing Industrial Co., Ltd., Shanghai, China, and Qingdao Fraken International Trading Co., Ltd., Shandong, China, respectively.</p></sec><sec><title>Ethical statement</title><p>The Research Ethics Committee For Oncology of Huzhou Central Hospital, China, approved the experimental protocol, and the ethics guidelines for oncology research on human subjects in accordance with the Chinese law were followed [<xref rid="b13-medscimonit-24-1970" ref-type="bibr">13</xref>].</p></sec><sec><title>Diagnosis and surgical resection</title><p>Patients suspected to have rectal cancer underwent rectal colonoscopy [<xref rid="b14-medscimonit-24-1970" ref-type="bibr">14</xref>], CT-scan, and high-resolution rectal MRI [<xref rid="b15-medscimonit-24-1970" ref-type="bibr">15</xref>]. During the diagnosis process, patients who were found to have rectal tumors and who required surgical resection were recommended for surgery. After getting written informed consent from the patients or their relatives, the patients underwent rectal surgery [<xref rid="b16-medscimonit-24-1970" ref-type="bibr">16</xref>].</p></sec><sec><title>Detection of stage of cancer</title><sec sec-type="methods"><title>Analysis of KRAS gene mutation</title><p>Tumors removed by surgical resection was frozen in a Dwc-196 liquid nitrogen refrigeration low-temperature chamber (HST Group Co., Ltd., Shandong, China). The DNA from tumors was extracted using a blood and tissue DNA extraction mini kit (Guangzhou Changyu Biotechnology Co., Ltd., Guangzhou, China), then polymerase chain reaction and exon 1 and 3 were sequenced. Direct sequencing was carried out using the CA-40212E kit (Changsha Aube Didactic Equipment Co., Ltd., Hunan, China) [<xref rid="b6-medscimonit-24-1970" ref-type="bibr">6</xref>].</p></sec><sec><title>Histopathology</title><p>We collected a 4-mm sample of tissue from the surgically resected tumor. The sample was fixed in 10% formalin. The specimen was stained with hematoxylin and eosin and observed under a binocular stereo microscope with top and bottom light illumination (M633c, Chongqing Dontop Optics Co., Ltd., Chongqing, China) under 10&#x000d7; and 45&#x000d7; [<xref rid="b15-medscimonit-24-1970" ref-type="bibr">15</xref>].</p><p>In the above pathological and clinical data, biopsies and autopsies were considered for analysis. By using the TNM rectal carcinoma staging system, the stage of cancer was detected at baseline (<xref ref-type="table" rid="t1-medscimonit-24-1970">Table 1</xref>) [<xref rid="b17-medscimonit-24-1970" ref-type="bibr">17</xref>].</p></sec></sec><sec><title>Aim</title><sec><title>Primary aim</title><p>Clinicopathology. The primary aim of the study was the clinicopathological response of the patients&#x02019; body after chemotherapeutic treatment.</p></sec><sec><title>Secondary aim</title><p>Treatment-emergent adverse effects. A secondary aim of the study was overall survival, cancer-free conditions, and toxicities.</p></sec></sec><sec><title>Inclusion criteria</title><p>We included rectal cancer patients with advanced adenocarcinoma of the rectum who were admitted to the Department of Anorectal Surgery and the Department of Hepatobiliary Surgery, Huzhou Central Hospital, Huzhou, China during January 2008 to March 2017, and who were age 18&#x02013;70 years, had a 0&#x02013;8 cm distance margin of the tumor from the anal verge, and had no prior chemotherapy exposure. All subjects were over 18 years of age and gave informed consent for chemotherapeutic treatment and publication in educational magazines, journals, textbooks in any form or medium (including all forms of electronic publication or distribution) anywhere in the world without time limit. Data were available from patients&#x02019; DCOIM files of Huzhou Central Hospital, Zhejiang, China.</p></sec><sec><title>Exclusion criteria</title><p>We excluded patients who had impaired renal function, liver function, or and inadequate blood cell counts were excluded from the study as were patients who refused MRI or surgery, or who had incomplete histopathology and KRAS gene mutation data.</p></sec><sec><title>Chemotherapy treatment and sample size</title><p>The demographical parameters of the patients involved in the study are reported in <xref ref-type="table" rid="t2-medscimonit-24-1970">Table 2</xref>. After surgery, those patients who were refused and were not administered chemotherapy and radiotherapy after surgery were included in the control group. Those patients who received FOLFOX4 chemotherapeutic regimen (200 mg/m<sup>2</sup> FA, 400 mg/m<sup>2</sup> 5-FU, and 85 mg/m<sup>2</sup> OP) as 2 h infusion for 12 cycles and cycle/2weeks following radiotherapy after surgery [<xref rid="b4-medscimonit-24-1970" ref-type="bibr">4</xref>] were included in the FFO group. Those patients who received FOLFIRINOX chemotherapeutic regimen (400 mg/m<sup>2</sup> FA, 400 mg/m<sup>2</sup> 5-FU, 180 mg/m<sup>2</sup> IT, and 85 mg/m<sup>2</sup> OP) as 2 h infusion for 25 cycles and cycle/2 weeks following radiotherapy [<xref rid="b18-medscimonit-24-1970" ref-type="bibr">18</xref>] were included in the FFIO group.</p><p>For optimum statistical analysis, the sample size was 150 for each group. The flow chart of chemotherapeutic treatment is shown in <xref ref-type="fig" rid="f1-medscimonit-24-1970">Figure 1</xref>.</p></sec><sec><title>Pathological response</title><p>In rectal cancer, carbohydrate antigen 19-9 and serum carcinoembryonic antigen are tumor markers [<xref rid="b19-medscimonit-24-1970" ref-type="bibr">19</xref>]. A blood sample of patients was collected after each cycle of chemotherapy. Carbohydrate antigen 19-9 and serum carcinoembryonic antigen in blood samples were evaluated by a pathologist who was blind to the chemotherapeutic treatments [<xref rid="b20-medscimonit-24-1970" ref-type="bibr">20</xref>].</p></sec><sec><title>Cost of treatment</title><p>The total cost of treatment included costs related to diagnosis before surgery, chemotherapy, radiotherapy, follow-up visits, and diagnosis in follow-up. However, the charges did not include the treatment of adverse effects and related hospitalization. Travel costs from home to hospital were not counted in the cost of treatment. A bootstrap procedure was used for evaluating the cost of treatment in all groups [<xref rid="b21-medscimonit-24-1970" ref-type="bibr">21</xref>].</p></sec><sec><title>Treatment-emergent adverse effects</title><p>Approval from the Central Research Ethics Committee for the Oncology Society of China was obtained for evaluation and analysis of treatment-emergent adverse effects. Fatal and non-fatal and treatment-emergent adverse effects of chemotherapy such as neutropenia, thrombocytopenia, nausea, vomiting, stomatitis, diarrhea, hepatic diseases, fatigue, peripheral neurotoxicity, skin rashes, and pulmonary complications were evaluated during follow-up. Neutropenia, thrombocytopenia, pulmonary complications, and hepatic diseases were evaluated from a blood sample collected and using the 3-Part Blood Cell Counter (Henan Forever Medical Co., Ltd. Henan, China). Peripheral neurotoxicity was evaluated by an expert neurologist available in the hospital. Nausea, vomiting, skin rashes, stomatitis, diarrhea, and fatigue were assessed by a questionnaire administered to patients [<xref rid="b4-medscimonit-24-1970" ref-type="bibr">4</xref>].</p></sec><sec><title>Cancer recurrence</title><p>After completion of chemotherapy, all radiological and pathological data were evaluated every 6 months. The liver is the most prominent site for metastasis in rectal cancer [<xref rid="b5-medscimonit-24-1970" ref-type="bibr">5</xref>]. Recurrence was considered if patients had a positive rectal, liver, pulmonary, or colon tumor. To check the recurrence, rectal biopsy or autopsy were carried out every 6 months [<xref rid="b13-medscimonit-24-1970" ref-type="bibr">13</xref>]. The response of tumor recurrence to chemotherapy was evaluated by RECIST (Response Evaluation Criteria In Solid Tumors) guidelines [<xref rid="b22-medscimonit-24-1970" ref-type="bibr">22</xref>].</p></sec><sec><title>Overall survival</title><p>Overall survival irrespective of cancer-free conditions was also evaluated after completion of treatments for each group during follow-up [<xref rid="b7-medscimonit-24-1970" ref-type="bibr">7</xref>].</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>Ordinary ANOVA was performed for tumor staging, nodal-staging, and pathological responses before surgery among the groups. Two-tailed <italic>t</italic> tests (considering &#x003b2;=0.1 and &#x003b1;=0.05) [<xref rid="b23-medscimonit-24-1970" ref-type="bibr">23</xref>] following Turkey post hoc test (considering <italic>q</italic>&#x0003e;3.331 for significant) were used for anatomical characteristics of enrolled patients, fatal and non-fatal chemotherapeutic treatment-emergent adverse effects after complication of all cycles, total cancer recurrence analysis, only rectal cancer recurrence analysis, and cost of treatment. Wilcoxon rank sum test (considering <italic>q</italic>&#x0003e;3.331 for significant) was performed for tumor and nodal staging and clinicopathological responses between before surgery and after completion of total treatment(s) [<xref rid="b24-medscimonit-24-1970" ref-type="bibr">24</xref>]. All statistical tests were performed using InstatGraphPad software (GraphPad Software, Inc., CA). The results of parameters were considered significant at 99% confidence level for anatomical characteristics, tumor staging, nodal staging, and pathological responses of enrolled patients before surgery. However, the results of parameters were considered significant at 95% confidence level for fatal and non-fatal chemotherapeutic treatment-emergent adverse effects, tumor staging, cost of treatment, overall survival irrespective of cancer-free condition, total cancer, and only rectal recurrence analysis after treatment.</p></sec></sec><sec sec-type="results"><title>Results</title><p>There were no differences between groups in anatomical or cancerous characteristics of enrolled patients at baseline (<italic>p</italic>&#x02265;0.05 for all characteristics).</p><p>There was no difference in tumor staging (<italic>p</italic>=0.1248) and nodal staging (<italic>p</italic>=0.2516) among the group before surgery. After surgery or chemotherapy after surgery, following radiotherapy there were improved disease-free conditions according to tumor staging and nodal staging in enrolled patients (<italic>p</italic>&#x02264;0.05 for both, <xref ref-type="table" rid="t3-medscimonit-24-1970">Table 3</xref>).</p><p>Surgery only did not sufficiently decrease elevated levels of carbohydrate antigen (<italic>p</italic>=0.0653) and carcinoembryonic antigen 19-9 (<italic>p</italic>=0.0592). However, after surgery, chemotherapy following radiotherapy succeeded in maintaining elevated levels of carbohydrate antigen and carcinoembryonic antigen 19-9 (<italic>p</italic>&#x02264;0.05 for both, <xref ref-type="table" rid="t4-medscimonit-24-1970">Table 4</xref>).</p><p>The cost of chemotherapeutic treatments was in the order of FFIO group &#x0003e; FFO group &#x0003e; control group (<xref ref-type="fig" rid="f2-medscimonit-24-1970">Figure 2</xref>).</p><p>Non-fatal treatment-emergent adverse effects were due to chemotherapeutic drugs only (<italic>p</italic>&#x02264;0.05 for all effects). However, fatal chemotherapeutic treatment-emergent adverse effects were observed only in the FFIO group (p=0.00001 for all effects, <xref ref-type="table" rid="t5-medscimonit-24-1970">Table 5</xref>).</p><p>The FFIO group had more rectal cancer-free patients than in the FFO and Control groups during 90 months of follow-up (<italic>p</italic>&#x02264;0.05, <xref ref-type="fig" rid="f3-medscimonit-24-1970">Figure 3</xref>).</p><p>Overall survival irrespective of diseased condition was higher in the FFO group than in the Control and FFIO groups during 90 months of follow-up (<italic>p</italic>&#x02264;0.05, <xref ref-type="fig" rid="f4-medscimonit-24-1970">Figure 4</xref>).</p><p>Total cancer-free conditions were decreased as the follow-up time increased in all 3 groups (<italic>p</italic>&#x02264;0.05, <xref ref-type="table" rid="t6-medscimonit-24-1970">Table 6</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>FOLFOX4 and FOLFIRINOX regimens satisfactorily controlled elevated levels of carbohydrate antigen and carcinoembryonic antigen in Chinese rectal cancer patients. Surgery only failed to control pathological responses of cancerous conditions [<xref rid="b20-medscimonit-24-1970" ref-type="bibr">20</xref>]. The data were identical with the use of these regimens in the other cancer treatment [<xref rid="b25-medscimonit-24-1970" ref-type="bibr">25</xref>]. To the best of our knowledge, the present study is the first to succeed in maintaining pathological responses in cancerous conditions in a Chinese population.</p><p>The cost of chemotherapeutic treatments was high, and overall survival irrespective of cancerous condition was less in the FFIO group than in the FFO group. FFIO regimens have more of cycles, more chemotherapeutic drugs, and higher scheduled and unscheduled costs than the FFO regimen [<xref rid="b21-medscimonit-24-1970" ref-type="bibr">21</xref>]. The cost and overall survival analyses can assist decision-making in the selection of chemotherapeutic treatment regimens in rectal cancer.</p><p>There were more deaths in the FFIO group as compared to the FFO group. FOLFIRINOX is an aggressive regimen in rectal cancer, which has high rate of fatal chemotherapeutic treatment-emergent adverse effects [<xref rid="b16-medscimonit-24-1970" ref-type="bibr">16</xref>]. In respect to selecting the FOLFIRINOX chemotherapeutic regimen, FOLFIRINOX should be used in advanced rectal cancer to control tumors.</p><p>There were more deaths in the Control group than in the FFO and FFIO groups. Surgery after diagnosis of rectal cancer or surgery following chemotherapy and radiotherapy is necessary for improvement of tumor staging and nodal-staging in rectal cancer patients [<xref rid="b2-medscimonit-24-1970" ref-type="bibr">2</xref>]. However, surgical resection only leads to more chance of recurrence [<xref rid="b7-medscimonit-24-1970" ref-type="bibr">7</xref>]. With respect to the choice of treatment for rectal cancer, chemotherapy improved the overall survival of patients, irrespective of disease condition.</p><p>There were fewer total cancer recurrence patients in the FFIO group than in the Control and FFO groups. The FOLFIRINOX regimen is predominantly used when patients have a high risk of metastasis [<xref rid="b16-medscimonit-24-1970" ref-type="bibr">16</xref>] and was found to be safer safe than and superior to gemcitabine [<xref rid="b26-medscimonit-24-1970" ref-type="bibr">26</xref>]. However, the FOLFOX4 regimen is used as the standard first-line chemotherapeutic treatment in rectal cancer [<xref rid="b4-medscimonit-24-1970" ref-type="bibr">4</xref>], and surgical resection is the standard of care for rectal cancer [<xref rid="b13-medscimonit-24-1970" ref-type="bibr">13</xref>]. In considering the analysis of outcome measures and treatment-emergent adverse effects, our study provides useful information for selection of a suitable regimen of chemotherapeutic agents according to stage of rectal cancer.</p><p>Limitations of the present study include the fact that the secondary effects of the combination of FOLFIRINOX and gemcitabine or FOLFOX4 and gemcitabine were not evaluated. The study was focussed on chemotherapeutic regimens only. The study did not evaluate radiological parameters related to treatment-emergent adverse effects and did not provide bifurcations of the cost of treatment. Sensitivity analyses testing was not reported in the manuscript. The survival data were generated to provide information on whether there was a systemic relapse.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The published ethical guidelines for oncologists conclude that FOLFOX4 or FOLFIRINOX are necessary after rectal cancer surgery to overcome recurrence. Total cancer recurrence was less in the FOLFIRINOX group than in the FOLFOX4 group. However, fatal treatment-emergent adverse effects and cost of treatment were higher in the FOLFIRINOX group than in the FOLFOX4 group. However, overall survival, irrespective of cancerous condition, was higher in the FOLFOX4 group than in the FOLFIRINOX group. Specifically designed chemotherapeutic regimens are required fit the patient profile.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank all the individuals, healthcare providers, technicians, and administrative staff of Huzhou Central Hospital, China who enabled this work to be carried out.</p></ack><fn-group><fn id="fn9-medscimonit-24-1970"><p><bold>Source of support:</bold> Departmental sources</p></fn><fn id="fn10-medscimonit-24-1970" fn-type="COI-statement"><p><bold>Conflict of interest</bold></p><p>None.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-24-1970"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y-F</given-names></name><name><surname>Du</surname><given-names>C-Z</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: A potential biomarker predictive of metastasis</article-title><source>Dis Colon Rectum</source><year>2013</year><volume>57</volume><fpage>602</fpage><lpage>7</lpage></element-citation></ref><ref id="b2-medscimonit-24-1970"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trakarnsanga</surname><given-names>A</given-names></name><name><surname>Ithimakin</surname><given-names>S</given-names></name><name><surname>Weiser</surname><given-names>MR</given-names></name></person-group><article-title>Treatment of locally advanced rectal cancer: Controversies and questions</article-title><source>World J Gastroenterol</source><year>2012</year><volume>18</volume><fpage>5521</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">23112544</pub-id></element-citation></ref><ref id="b3-medscimonit-24-1970"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>SH</given-names></name><name><surname>Harling</surname><given-names>H</given-names></name><name><surname>Kirkeby</surname><given-names>LT</given-names></name><etal/></person-group><article-title>Postoperative adjuvant chemotherapy in rectal cancer operated for cure</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><issue>3</issue><fpage>CD004078</fpage><pub-id pub-id-type="pmid">22419291</pub-id></element-citation></ref><ref id="b4-medscimonit-24-1970"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Sung</surname><given-names>JY</given-names></name><name><surname>Han</surname><given-names>S-H</given-names></name><etal/></person-group><article-title>Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: A Korean single-center Experience</article-title><source>Jpn J Clin Oncol</source><year>2005</year><volume>35</volume><fpage>531</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">16027146</pub-id></element-citation></ref><ref id="b5-medscimonit-24-1970"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasan</surname><given-names>HS</given-names></name><name><surname>Gibbs</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>NK</given-names></name><etal/></person-group><collab>FOXFIRE trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators</collab><person-group person-group-type="author"><name><surname>Hazel</surname><given-names>GV</given-names></name><name><surname>Sharma</surname><given-names>RA</given-names></name></person-group><article-title>First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A combined analysis of three multicenter, randomized, phase 3 trials</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><issue>9</issue><fpage>1159</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">28781171</pub-id></element-citation></ref><ref id="b6-medscimonit-24-1970"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Hong</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><etal/></person-group><article-title>Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: A multicenter phase II study</article-title><source>Int J Radiation Oncology Biol Phys</source><year>2011</year><volume>81</volume><fpage>677</fpage><lpage>83</lpage></element-citation></ref><ref id="b7-medscimonit-24-1970"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanel</surname><given-names>SC</given-names></name><name><surname>Sjoberg</surname><given-names>J</given-names></name><name><surname>Salmonson</surname><given-names>T</given-names></name><etal/></person-group><article-title>European medicines agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer</article-title><source>ESMO Open</source><year>2017</year><volume>2</volume><issue>2</issue><fpage>e000190</fpage><pub-id pub-id-type="pmid">28761750</pub-id></element-citation></ref><ref id="b8-medscimonit-24-1970"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milinis</surname><given-names>K</given-names></name><name><surname>Thornton</surname><given-names>M</given-names></name><name><surname>Montazeri</surname><given-names>A</given-names></name><name><surname>Rooney</surname><given-names>PS</given-names></name></person-group><article-title>Adjuvant chemotherapy for rectal cancer: Is it needed?</article-title><source>World J Clin Oncol</source><year>2015</year><volume>6</volume><fpage>225</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">26677436</pub-id></element-citation></ref><ref id="b9-medscimonit-24-1970"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>K</given-names></name><name><surname>Yasui</surname><given-names>H</given-names></name><name><surname>Onozawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin, and taxanes: A retrospective study</article-title><source>Jpn J Clin Oncol</source><year>2012</year><volume>42</volume><fpage>686</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">22693245</pub-id></element-citation></ref><ref id="b10-medscimonit-24-1970"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>SR</given-names></name><name><surname>Benedetti</surname><given-names>JK</given-names></name><name><surname>Williamson</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>3542</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">16877719</pub-id></element-citation></ref><ref id="b11-medscimonit-24-1970"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolpin</surname><given-names>BM</given-names></name><name><surname>Meyerhardt</surname><given-names>JA</given-names></name><name><surname>Mamon</surname><given-names>HJ</given-names></name><name><surname>Mayer</surname><given-names>RJ</given-names></name></person-group><article-title>Adjuvant treatment of colorectal cancer</article-title><source>CA-Cancer J Clin</source><year>2009</year><volume>57</volume><fpage>168</fpage><lpage>85</lpage></element-citation></ref><ref id="b12-medscimonit-24-1970"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>RKS</given-names></name><name><surname>Tandan</surname><given-names>V</given-names></name><name><surname>De Silva</surname><given-names>S</given-names></name><name><surname>Figueredo</surname><given-names>A</given-names></name></person-group><article-title>Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma (review)</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><issue>2</issue><fpage>CD002102</fpage><pub-id pub-id-type="pmid">17443515</pub-id></element-citation></ref><ref id="b13-medscimonit-24-1970"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Flores</surname><given-names>E</given-names></name><name><surname>Losa</surname><given-names>F</given-names></name><name><surname>Pericay</surname><given-names>C</given-names></name><etal/></person-group><article-title>SEOM Clinical Guideline of localized rectal cancer (2016)</article-title><source>Clin Transl Oncol</source><year>2016</year><volume>18</volume><fpage>1163</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">27905053</pub-id></element-citation></ref><ref id="b14-medscimonit-24-1970"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balyasnikova</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>G</given-names></name></person-group><article-title>Optimal imaging strategies for rectal cancer staging and ongoing management</article-title><source>Curr Treat Options Oncol</source><year>2016</year><volume>17</volume><issue>6</issue><fpage>32</fpage><pub-id pub-id-type="pmid">27255100</pub-id></element-citation></ref><ref id="b15-medscimonit-24-1970"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>SK</given-names></name><name><surname>Bhangu</surname><given-names>A</given-names></name><name><surname>Tait</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Chemoradiotherapy response in recurrent rectal cancer</article-title><source>Cancer Med</source><year>2014</year><volume>3</volume><fpage>111</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">24403010</pub-id></element-citation></ref><ref id="b16-medscimonit-24-1970"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostwal</surname><given-names>V</given-names></name><name><surname>Engineer</surname><given-names>R</given-names></name><name><surname>Ramaswamy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX?</article-title><source>J Gastrointest Oncol</source><year>2016</year><volume>7</volume><fpage>958</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">28078119</pub-id></element-citation></ref><ref id="b17-medscimonit-24-1970"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name></person-group><article-title>The American Joint Committee on Cancer: The 7<sup>th</sup> Edition of the AJCC Cancer Staging Manual and the Future of TNM</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>17</volume><fpage>1471</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">20180029</pub-id></element-citation></ref><ref id="b18-medscimonit-24-1970"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneitler</surname><given-names>S</given-names></name><name><surname>Kropil</surname><given-names>P</given-names></name><name><surname>Riemer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><fpage>6384</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">26034375</pub-id></element-citation></ref><ref id="b19-medscimonit-24-1970"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokunaga</surname><given-names>R</given-names></name><name><surname>Sakamoto</surname><given-names>Y</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment</article-title><source>Surg Today</source><year>2016</year><volume>47</volume><fpage>636</fpage><lpage>42</lpage></element-citation></ref><ref id="b20-medscimonit-24-1970"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LN</given-names></name><name><surname>Xiao</surname><given-names>W-W</given-names></name><name><surname>Xi</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Pathological assessment of the AJCC tumor regression grading system after preoperative chemoradiotherapy for Chinese locally advanced rectal cancer</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><issue>3</issue><fpage>e2272</fpage><pub-id pub-id-type="pmid">26817863</pub-id></element-citation></ref><ref id="b21-medscimonit-24-1970"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>VC</given-names></name><name><surname>Ng</surname><given-names>WT</given-names></name><name><surname>Lee</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision making on reimbursement</article-title><source>BMC Cancer</source><year>2011</year><volume>11</volume><fpage>288</fpage><pub-id pub-id-type="pmid">21740590</pub-id></element-citation></ref><ref id="b22-medscimonit-24-1970"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stattaus</surname><given-names>J</given-names></name></person-group><article-title>Oncological imaging for therapy response assessment</article-title><source>Radiologe</source><year>2014</year><volume>54</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">24326357</pub-id></element-citation></ref><ref id="b23-medscimonit-24-1970"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrone</surname><given-names>CR</given-names></name><name><surname>Marchegiani</surname><given-names>G</given-names></name><name><surname>Hong</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer</article-title><source>Ann Surg</source><year>2015</year><volume>261</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">25599322</pub-id></element-citation></ref><ref id="b24-medscimonit-24-1970"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouanet</surname><given-names>P</given-names></name><name><surname>Rullier</surname><given-names>E</given-names></name><name><surname>Lelong</surname><given-names>B</given-names></name><etal/></person-group><collab>the GRECCAR Study Group</collab><article-title>Tailored treatment strategy for locally advanced rectal carcinoma based on the tumor response to induction chemotherapy: Preliminary results of the French phase II multicenter GRECCAR4 trial</article-title><source>Dis Colon Rectum</source><year>2017</year><volume>60</volume><fpage>653</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">28594714</pub-id></element-citation></ref><ref id="b25-medscimonit-24-1970"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christians</surname><given-names>KK</given-names></name><name><surname>Tsai</surname><given-names>S</given-names></name><name><surname>Mahmoud</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: A new treatment paradigm?</article-title><source>Oncologist</source><year>2014</year><volume>19</volume><fpage>266</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">24569947</pub-id></element-citation></ref><ref id="b26-medscimonit-24-1970"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peixoto</surname><given-names>RD</given-names></name><name><surname>Ho</surname><given-names>M</given-names></name><name><surname>Renouf</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX</article-title><source>Am J Clin Oncol</source><year>2015</year><comment>[Epub ahead of print]</comment></element-citation></ref></ref-list></back><floats-group><fig id="f1-medscimonit-24-1970" position="float"><label>Figure 1</label><caption><p>Chemotherapeutic treatment arms of the clinical experimental study.</p></caption><graphic xlink:href="medscimonit-24-1970-g001"/></fig><fig id="f2-medscimonit-24-1970" position="float"><label>Figure 2</label><caption><p>Cost of chemotherapeutic treatments. n=150 for all groups. Data are represented as mean &#x000b1;SD. Bootstrap procedure.</p></caption><graphic xlink:href="medscimonit-24-1970-g002"/></fig><fig id="f3-medscimonit-24-1970" position="float"><label>Figure 3</label><caption><p>Only rectal cancer recurrence analysis as per treatment. For statistical analysis, the rectal cancer condition of the patient was considered as 1 and rectal cancer-free condition of the patient was considered as 0. RECIST guidelines evaluation. Scores were higher in the FFIO group than in the FFO and Control groups during follow-up (<italic>p</italic>&#x02264;0.05).</p></caption><graphic xlink:href="medscimonit-24-1970-g003"/></fig><fig id="f4-medscimonit-24-1970" position="float"><label>Figure 4</label><caption><p>Overall survival irrespective of cancerous condition analysis as per treatment. For statistical analysis, survival, irrespective of disease condition, was considered as 0, and death due to any condition was considered as 1. Scores were higher in the FFO group than in the Control and FFIO groups (<italic>p</italic>&#x02264;0.05).</p></caption><graphic xlink:href="medscimonit-24-1970-g004"/></fig><table-wrap id="t1-medscimonit-24-1970" position="float"><label>Table 1</label><caption><p>Rectal carcinoma staging as per TNM system.</p></caption><table frame="hsides" rules="rows"><thead><tr><th colspan="2" valign="middle" align="center" rowspan="1">T: Tumor</th><th colspan="2" valign="middle" align="center" rowspan="1">N: Nodes</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">T0</td><td valign="middle" align="left" rowspan="1" colspan="1">No evidence of primary tumor</td><td valign="middle" align="center" rowspan="1" colspan="1">NO</td><td valign="middle" align="left" rowspan="1" colspan="1">No evidence of node</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T1</td><td valign="middle" align="left" rowspan="1" colspan="1">Site specific tumor (small)</td><td valign="middle" align="center" rowspan="1" colspan="1">N1</td><td valign="middle" align="left" rowspan="1" colspan="1">Site specific tumor (small)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T2</td><td valign="middle" align="left" rowspan="1" colspan="1">Site specific tumor (medium)</td><td valign="middle" align="center" rowspan="1" colspan="1">N2</td><td valign="middle" align="left" rowspan="1" colspan="1">Site specific tumor (medium)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T3</td><td valign="middle" align="left" rowspan="1" colspan="1">Site specific tumor (large)</td><td valign="middle" align="center" rowspan="1" colspan="1">N3</td><td valign="middle" align="left" rowspan="1" colspan="1">Site specific tumor (large)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T4a</td><td valign="middle" align="left" rowspan="1" colspan="1">tumor infiltrates the serosa</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T4b</td><td valign="middle" align="left" rowspan="1" colspan="1">Site specific tumor adjacent to tissue</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="t2-medscimonit-24-1970" position="float"><label>Table 2</label><caption><p>Anatomical characteristics of enrolled patients.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" rowspan="2" align="center" colspan="1">Characteristics</th><th valign="middle" align="center" rowspan="1" colspan="1">Group</th><th valign="middle" align="center" rowspan="1" colspan="1">Control</th><th valign="middle" align="center" rowspan="1" colspan="1">FFO</th><th valign="middle" align="center" rowspan="1" colspan="1">FFIO</th><th valign="middle" rowspan="2" align="center" colspan="1"><italic>p</italic> Value for variations among the groups</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Sample size</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th></tr></thead><tbody><tr><td valign="middle" rowspan="2" align="left" colspan="1">Surgical resection</td><td valign="middle" align="left" rowspan="1" colspan="1">Abdominal-perianal</td><td valign="middle" align="center" rowspan="1" colspan="1">79 (69)</td><td valign="middle" align="center" rowspan="1" colspan="1">77 (67)</td><td valign="middle" align="center" rowspan="1" colspan="1">71 (62)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.5142</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Anterior</td><td valign="middle" align="center" rowspan="1" colspan="1">36 (31)</td><td valign="middle" align="center" rowspan="1" colspan="1">38 (33)</td><td valign="middle" align="center" rowspan="1" colspan="1">44 (38)</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Time from surgery to treatment</td><td valign="middle" align="left" rowspan="1" colspan="1">20&#x02013;40 days</td><td valign="middle" align="center" rowspan="1" colspan="1">66 (57)</td><td valign="middle" align="center" rowspan="1" colspan="1">48 (42)</td><td valign="middle" align="center" rowspan="1" colspan="1">50 (43)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.1148</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02265;41 days</td><td valign="middle" align="center" rowspan="1" colspan="1">49 (43)</td><td valign="middle" align="center" rowspan="1" colspan="1">67 (58)</td><td valign="middle" align="center" rowspan="1" colspan="1">65 (57)</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Gender</td><td valign="middle" align="left" rowspan="1" colspan="1">Male</td><td valign="middle" align="center" rowspan="1" colspan="1">76 (66)</td><td valign="middle" align="center" rowspan="1" colspan="1">72 (63)</td><td valign="middle" align="center" rowspan="1" colspan="1">69 (60)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.6337</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Female</td><td valign="middle" align="center" rowspan="1" colspan="1">39 (34)</td><td valign="middle" align="center" rowspan="1" colspan="1">43 (37)</td><td valign="middle" align="center" rowspan="1" colspan="1">46 (40)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age (years) (mean &#x000b1;SD)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">57.95&#x000b1;2.61</td><td valign="middle" align="center" rowspan="1" colspan="1">58.52&#x000b1;2.01</td><td valign="middle" align="center" rowspan="1" colspan="1">56.42&#x000b1;2.69</td><td valign="middle" align="center" rowspan="1" colspan="1">0.1283</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>) (mean &#x000b1;SD)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">24.12&#x000b1;1.12</td><td valign="middle" align="center" rowspan="1" colspan="1">25.22&#x000b1;1.45</td><td valign="middle" align="center" rowspan="1" colspan="1">23.56&#x000b1;1.35</td><td valign="middle" align="center" rowspan="1" colspan="1">0.4562</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">Distance margin of tumor from anal verge (cm)</td><td valign="middle" align="left" rowspan="1" colspan="1">0&#x02013;5</td><td valign="middle" align="center" rowspan="1" colspan="1">83 (72)</td><td valign="middle" align="center" rowspan="1" colspan="1">67 (58)</td><td valign="middle" align="center" rowspan="1" colspan="1">65 (57)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.1059</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">5&#x02013;8</td><td valign="middle" align="center" rowspan="1" colspan="1">32 (28)</td><td valign="middle" align="center" rowspan="1" colspan="1">48 (42)</td><td valign="middle" align="center" rowspan="1" colspan="1">50 (43)</td></tr><tr><td valign="middle" rowspan="3" align="left" colspan="1">Tumor differentiation</td><td valign="middle" align="left" rowspan="1" colspan="1">Poorly differentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">8 (7)</td><td valign="middle" align="center" rowspan="1" colspan="1">9 (8)</td><td valign="middle" align="center" rowspan="1" colspan="1">11 (10)</td><td valign="middle" rowspan="3" align="center" colspan="1">0.4904</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Moderately differentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">88 (77)</td><td valign="middle" align="center" rowspan="1" colspan="1">83 (72)</td><td valign="middle" align="center" rowspan="1" colspan="1">87 (76)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Well differentiated</td><td valign="middle" align="center" rowspan="1" colspan="1">19 (16)</td><td valign="middle" align="center" rowspan="1" colspan="1">23 (20)</td><td valign="middle" align="center" rowspan="1" colspan="1">17 (14)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-24-1970"><p>Data were represented as Number (Percentage). No changes for anatomical and cancerous characteristics of enrolled patients between groups.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-medscimonit-24-1970" position="float"><label>Table 3</label><caption><p>Tumor staging according to American Joint Committee on Cancer classification system for oncology before and after chemotherapy following radiotherapy treatment.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Group</th><th colspan="4" valign="middle" align="center" rowspan="1">Control)</th><th colspan="4" valign="middle" align="center" rowspan="1">FFO</th><th colspan="4" valign="middle" align="center" rowspan="1">FFIO</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Level</th><th valign="middle" align="center" rowspan="1" colspan="1">BL</th><th valign="middle" align="center" rowspan="1" colspan="1">EP</th><th valign="middle" rowspan="2" align="center" colspan="1"><italic>p</italic></th><th valign="middle" rowspan="2" align="center" colspan="1"><italic>q</italic></th><th valign="middle" align="center" rowspan="1" colspan="1">BL</th><th valign="middle" align="center" rowspan="1" colspan="1">EP</th><th valign="middle" rowspan="2" align="center" colspan="1"><italic>p</italic></th><th valign="middle" rowspan="2" align="center" colspan="1"><italic>q</italic></th><th valign="middle" align="center" rowspan="1" colspan="1">BL</th><th valign="middle" align="center" rowspan="1" colspan="1">EP</th><th valign="middle" rowspan="2" align="center" colspan="1"><italic>p</italic></th><th valign="middle" rowspan="2" align="center" colspan="1"><italic>q</italic></th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Sample size</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th></tr></thead><tbody><tr><td colspan="13" valign="middle" align="center" rowspan="1">Tumor-staging</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T0</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">6 (5)</td><td valign="middle" rowspan="6" align="center" colspan="1">0.00089</td><td valign="middle" rowspan="6" align="center" colspan="1">14.606</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">21 (18)</td><td valign="middle" rowspan="6" align="center" colspan="1">0.000167</td><td valign="middle" rowspan="6" align="center" colspan="1">18.455</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">25 (22)</td><td valign="middle" rowspan="6" align="center" colspan="1">0.00013</td><td valign="middle" rowspan="6" align="center" colspan="1">31.559</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T1</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">19 (17)</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">19 (17)</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">41 (36)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T2</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">31 (30)</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">37 (32)</td><td valign="middle" align="right" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">33 (29)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T3</td><td valign="middle" align="right" rowspan="1" colspan="1">83 (72)</td><td valign="middle" align="right" rowspan="1" colspan="1">44 (38)</td><td valign="middle" align="right" rowspan="1" colspan="1">79 (69)</td><td valign="middle" align="right" rowspan="1" colspan="1">29 (25)</td><td valign="middle" align="right" rowspan="1" colspan="1">73 (63)</td><td valign="middle" align="right" rowspan="1" colspan="1">12 (10)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T4a</td><td valign="middle" align="right" rowspan="1" colspan="1">21 (18)</td><td valign="middle" align="right" rowspan="1" colspan="1">10 (7)</td><td valign="middle" align="right" rowspan="1" colspan="1">22 (19)</td><td valign="middle" align="right" rowspan="1" colspan="1">7 (6)</td><td valign="middle" align="right" rowspan="1" colspan="1">19 (17)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (3)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T4b</td><td valign="middle" align="right" rowspan="1" colspan="1">11 (10)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (3)</td><td valign="middle" align="right" rowspan="1" colspan="1">14 (12)</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (2)</td><td valign="middle" align="right" rowspan="1" colspan="1">23 (20)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (1)</td></tr><tr><td colspan="13" valign="middle" align="center" rowspan="1">Nodal-staging</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">N0</td><td valign="middle" align="right" rowspan="1" colspan="1">28 (24)</td><td valign="middle" align="right" rowspan="1" colspan="1">47 (41)</td><td valign="middle" rowspan="4" align="center" colspan="1">0.00019</td><td valign="middle" rowspan="4" align="center" colspan="1">4.379</td><td valign="middle" align="right" rowspan="1" colspan="1">26 (23)</td><td valign="middle" align="right" rowspan="1" colspan="1">44 (38)</td><td valign="middle" rowspan="4" align="center" colspan="1">0.0002</td><td valign="middle" rowspan="4" align="center" colspan="1">6.279</td><td valign="middle" align="right" rowspan="1" colspan="1">23 (20)</td><td valign="middle" align="right" rowspan="1" colspan="1">59 (51)</td><td valign="middle" rowspan="4" align="center" colspan="1">0.00001</td><td valign="middle" rowspan="4" align="center" colspan="1">11.261</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">N1</td><td valign="middle" align="right" rowspan="1" colspan="1">17 (15)</td><td valign="middle" align="right" rowspan="1" colspan="1">16 (14)</td><td valign="middle" align="right" rowspan="1" colspan="1">18 (16)</td><td valign="middle" align="right" rowspan="1" colspan="1">27 (23)</td><td valign="middle" align="right" rowspan="1" colspan="1">17 (15)</td><td valign="middle" align="right" rowspan="1" colspan="1">11 (10)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">N2</td><td valign="middle" align="right" rowspan="1" colspan="1">61 (53)</td><td valign="middle" align="right" rowspan="1" colspan="1">44 (38)</td><td valign="middle" align="right" rowspan="1" colspan="1">58 (50)</td><td valign="middle" align="right" rowspan="1" colspan="1">35 (30)</td><td valign="middle" align="right" rowspan="1" colspan="1">63 (55)</td><td valign="middle" align="right" rowspan="1" colspan="1">43 (37)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">N3</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (8)</td><td valign="middle" align="right" rowspan="1" colspan="1">8 (7)</td><td valign="middle" align="right" rowspan="1" colspan="1">13 (11)</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (8)</td><td valign="middle" align="right" rowspan="1" colspan="1">12 (10)</td><td valign="middle" align="right" rowspan="1" colspan="1">2 (2)</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-medscimonit-24-1970"><p>BL &#x02013; before surgery; EP &#x02013; after completion of total treatment(s). Data were represented as Number (Percentage). <italic>p</italic> value for Wilcoxon rank sum test; <italic>q</italic> value for Turkey <italic>post hoc</italic> test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-medscimonit-24-1970" position="float"><label>Table 4</label><caption><p>Effect of chemotherapeutic treatment on clinicopathological responses after complication of treatment.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" rowspan="3" align="center" colspan="1">Pathological parameters</th><th valign="middle" align="center" rowspan="1" colspan="1">Group</th><th colspan="3" valign="middle" align="center" rowspan="1">Control</th><th colspan="4" valign="middle" align="center" rowspan="1">FFO</th><th colspan="4" valign="middle" align="center" rowspan="1">FFIO</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Level</th><th valign="middle" align="center" rowspan="1" colspan="1">BL</th><th valign="middle" align="center" rowspan="1" colspan="1">EP</th><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">BL</th><th valign="middle" align="center" rowspan="1" colspan="1">EP</th><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">BL</th><th valign="middle" align="center" rowspan="1" colspan="1">EP</th><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Sample size</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>q</italic></th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>q</italic></th></tr></thead><tbody><tr><td valign="middle" rowspan="2" align="center" colspan="1">CA19-9</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02264;27 ng/L</td><td valign="middle" align="center" rowspan="1" colspan="1">17 (15)</td><td valign="middle" align="center" rowspan="1" colspan="1">37 (32)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.0653</td><td valign="middle" align="center" rowspan="1" colspan="1">21 (18)</td><td valign="middle" align="center" rowspan="1" colspan="1">67 (58)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.0029</td><td valign="middle" rowspan="2" align="center" colspan="1">5.432</td><td valign="middle" align="right" rowspan="1" colspan="1">14 (12)</td><td valign="middle" align="center" rowspan="1" colspan="1">94 (82)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.0018</td><td valign="middle" rowspan="2" align="center" colspan="1">7.532</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;27 ng/L</td><td valign="middle" align="center" rowspan="1" colspan="1">98 (85)</td><td valign="middle" align="center" rowspan="1" colspan="1">78 (68)</td><td valign="middle" align="center" rowspan="1" colspan="1">94 (82)</td><td valign="middle" align="center" rowspan="1" colspan="1">48 (42)</td><td valign="middle" align="right" rowspan="1" colspan="1">101 (88)</td><td valign="middle" align="center" rowspan="1" colspan="1">21 (18)</td></tr><tr><td valign="middle" rowspan="2" align="center" colspan="1">CEA</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02264;5 ng/L</td><td valign="middle" align="center" rowspan="1" colspan="1">34 (30)</td><td valign="middle" align="center" rowspan="1" colspan="1">49 (43)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.0592</td><td valign="middle" align="center" rowspan="1" colspan="1">23 (20)</td><td valign="middle" align="center" rowspan="1" colspan="1">87 (77)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.0031</td><td valign="middle" rowspan="2" align="center" colspan="1">6.321</td><td valign="middle" align="right" rowspan="1" colspan="1">27 (23)</td><td valign="middle" align="center" rowspan="1" colspan="1">93 (81)</td><td valign="middle" rowspan="2" align="center" colspan="1">0.00098</td><td valign="middle" rowspan="2" align="center" colspan="1">8.534</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;5 ng/L</td><td valign="middle" align="center" rowspan="1" colspan="1">81 (70)</td><td valign="middle" align="center" rowspan="1" colspan="1">66 (57)</td><td valign="middle" align="center" rowspan="1" colspan="1">92 (80)</td><td valign="middle" align="center" rowspan="1" colspan="1">28 (23)</td><td valign="middle" align="right" rowspan="1" colspan="1">88 (67)</td><td valign="middle" align="center" rowspan="1" colspan="1">22 (19)</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-medscimonit-24-1970"><p>Data were represented as Number (Percentage). BL &#x02013; before surgery; EP &#x02013; after completion of total treatment(s). <italic>p</italic> value for Wilcoxon rank sum test; <italic>q</italic> value for Turkey <italic>post hoc</italic> test. CA19-9: carbohydrate antigen; CEA &#x02013; carcinoembryonic antigen.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-medscimonit-24-1970" position="float"><label>Table 5</label><caption><p>Fatal and non-fatal chemotherapeutic treatment emergent adverse effects after complication of treatment.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" rowspan="2" align="center" colspan="1">Type</th><th valign="middle" align="center" rowspan="1" colspan="1">Group</th><th valign="middle" align="center" rowspan="1" colspan="1">1 (Control)</th><th valign="middle" align="center" rowspan="1" colspan="1">2 (FFO)</th><th colspan="2" valign="middle" align="center" rowspan="1">1 <italic>vs.</italic> 2</th><th valign="middle" align="center" rowspan="1" colspan="1">3 (FFIO)</th><th colspan="2" valign="middle" align="center" rowspan="1">1 <italic>vs.</italic> 3</th><th colspan="2" valign="middle" align="center" rowspan="1">2 <italic>vs.</italic> 3</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Sample size</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>q</italic></th><th valign="middle" align="center" rowspan="1" colspan="1">115</th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>q</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>q</italic></th></tr></thead><tbody><tr><td valign="middle" rowspan="5" align="left" colspan="1">Fatal treatment emergent adverse effect</td><td valign="middle" align="left" rowspan="1" colspan="1">Neutropenia</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">3 (3)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.083</td><td valign="middle" align="right" rowspan="1" colspan="1">1.545</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (8)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0024</td><td valign="middle" align="right" rowspan="1" colspan="1">4.634</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0137</td><td valign="middle" align="right" rowspan="1" colspan="1">3.089</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Thrombocytopenia</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">5 (4)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0247</td><td valign="middle" align="right" rowspan="1" colspan="1">2.384</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (8)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0024</td><td valign="middle" align="right" rowspan="1" colspan="1">4.294</td><td valign="middle" align="right" rowspan="1" colspan="1">0.045</td><td valign="middle" align="right" rowspan="1" colspan="1">1.907</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hepatic diseases</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">7 (6)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0076</td><td valign="middle" align="right" rowspan="1" colspan="1">2.97</td><td valign="middle" align="right" rowspan="1" colspan="1">11 (10)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0007</td><td valign="middle" align="right" rowspan="1" colspan="1">4.667</td><td valign="middle" align="right" rowspan="1" colspan="1">0.045</td><td valign="middle" align="right" rowspan="1" colspan="1">1.697</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Peripheral neurotoxicity</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">1 (1)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.3194</td><td valign="middle" align="right" rowspan="1" colspan="1">0.542</td><td valign="middle" align="right" rowspan="1" colspan="1">8 (7)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0042</td><td valign="middle" align="right" rowspan="1" colspan="1">5.420</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0076</td><td valign="middle" align="right" rowspan="1" colspan="1">4.878</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pulmonary complications</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">9 (8)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0024</td><td valign="middle" align="right" rowspan="1" colspan="1">3.039</td><td valign="middle" align="right" rowspan="1" colspan="1">22 (19)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">7.428</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0002</td><td valign="middle" align="right" rowspan="1" colspan="1">4.389</td></tr><tr><td valign="middle" rowspan="6" align="left" colspan="1">Non-fatal treatment emergent adverse effect</td><td valign="middle" align="left" rowspan="1" colspan="1">Nausea<xref ref-type="table-fn" rid="tfn5-medscimonit-24-1970">*</xref></td><td valign="middle" align="center" rowspan="1" colspan="1">9 (8)</td><td valign="middle" align="right" rowspan="1" colspan="1">75 (65)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">16.806</td><td valign="middle" align="right" rowspan="1" colspan="1">108 (94)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">26.409</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">9.603</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Vomiting<xref ref-type="table-fn" rid="tfn5-medscimonit-24-1970">*</xref></td><td valign="middle" align="center" rowspan="1" colspan="1">1 (1)</td><td valign="middle" align="right" rowspan="1" colspan="1">35 (30)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">8.131</td><td valign="middle" align="right" rowspan="1" colspan="1">42 (37)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">9.805</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0002</td><td valign="middle" align="right" rowspan="1" colspan="1">1.674</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Stomatitis</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (1)</td><td valign="middle" align="right" rowspan="1" colspan="1">17 (15)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">4.74</td><td valign="middle" align="right" rowspan="1" colspan="1">23 (20)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">6.518</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0004</td><td valign="middle" align="right" rowspan="1" colspan="1">1.778</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Diarrhea</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (3)</td><td valign="middle" align="right" rowspan="1" colspan="1">8 (7)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0247</td><td valign="middle" align="right" rowspan="1" colspan="1">1.73</td><td valign="middle" align="right" rowspan="1" colspan="1">17 (15)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">4.843</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0001</td><td valign="middle" align="right" rowspan="1" colspan="1">3.113</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Fatigue</td><td valign="middle" align="center" rowspan="1" colspan="1">4 (3)</td><td valign="middle" align="right" rowspan="1" colspan="1">15 (13)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.007</td><td valign="middle" align="right" rowspan="1" colspan="1">4.29</td><td valign="middle" align="right" rowspan="1" colspan="1">27 (23)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">8.971</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0001</td><td valign="middle" align="right" rowspan="1" colspan="1">4.681</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">skin rashes</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="right" rowspan="1" colspan="1">12 (10)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0042</td><td valign="middle" align="right" rowspan="1" colspan="1">3.723</td><td valign="middle" align="right" rowspan="1" colspan="1">23 (20)</td><td valign="middle" align="right" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="right" rowspan="1" colspan="1">8.272</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0001</td><td valign="middle" align="right" rowspan="1" colspan="1">4.55</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-medscimonit-24-1970"><p>Data were represented as Number (Percentage). <italic>p</italic> value for two tailed <italic>t</italic>-tests; <italic>q</italic> value for Turkey <italic>post hoc</italic> test. For statistical analysis presence of adverse effect was considered as 1 and absence of that was considered as 0.</p></fn><fn id="tfn5-medscimonit-24-1970"><label>*</label><p>Patients had already taken anti-emetic.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-medscimonit-24-1970" position="float"><label>Table 6</label><caption><p>Total cancer recurrence analysis as per treatment.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" rowspan="4" align="center" colspan="1">Follow-up time (months)</th><th colspan="9" valign="middle" align="center" rowspan="1">Total cancer free patients (%)</th></tr><tr><th colspan="9" valign="middle" align="center" rowspan="1">Group</th></tr><tr><th valign="middle" rowspan="2" align="center" colspan="1">1 (Control)</th><th valign="middle" rowspan="2" align="center" colspan="1">2 (FFO)</th><th colspan="2" valign="middle" align="center" rowspan="1">1 <italic>vs.</italic> 2</th><th valign="middle" rowspan="2" align="center" colspan="1">3 (FFIO)</th><th colspan="2" valign="middle" align="center" rowspan="1">1 <italic>vs.</italic> 3</th><th colspan="2" valign="middle" align="center" rowspan="1">2 <italic>vs.</italic> 3</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>q</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>q</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>p</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>q</italic></th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">At EP</td><td valign="middle" align="right" rowspan="1" colspan="1">115 (100)</td><td valign="middle" align="right" rowspan="1" colspan="1">115 (100)</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="right" rowspan="1" colspan="1">115 (100)</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">6</td><td valign="middle" align="right" rowspan="1" colspan="1">85 (74)</td><td valign="middle" align="right" rowspan="1" colspan="1">110 (96)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.00001</td><td valign="middle" align="center" rowspan="1" colspan="1">8.155</td><td valign="middle" align="right" rowspan="1" colspan="1">114 (99)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000001</td><td valign="middle" align="center" rowspan="1" colspan="1">9.46</td><td valign="middle" align="center" rowspan="1" colspan="1">0.045</td><td valign="middle" align="center" rowspan="1" colspan="1">1.305</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">12</td><td valign="middle" align="right" rowspan="1" colspan="1">68 (47)</td><td valign="middle" align="right" rowspan="1" colspan="1">101 (88)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.00002</td><td valign="middle" align="center" rowspan="1" colspan="1">8.496</td><td valign="middle" align="right" rowspan="1" colspan="1">110 (96)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000002</td><td valign="middle" align="center" rowspan="1" colspan="1">10.813</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0024</td><td valign="middle" align="center" rowspan="1" colspan="1">2.317</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">18</td><td valign="middle" align="right" rowspan="1" colspan="1">50 (43)</td><td valign="middle" align="right" rowspan="1" colspan="1">92 (80)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.00003</td><td valign="middle" align="center" rowspan="1" colspan="1">9.697</td><td valign="middle" align="right" rowspan="1" colspan="1">105 (91)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000003</td><td valign="middle" align="center" rowspan="1" colspan="1">12.698</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0002</td><td valign="middle" align="center" rowspan="1" colspan="1">3.001</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">24</td><td valign="middle" align="right" rowspan="1" colspan="1">45 (39)</td><td valign="middle" align="right" rowspan="1" colspan="1">85 (74)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.00006</td><td valign="middle" align="center" rowspan="1" colspan="1">8.667</td><td valign="middle" align="right" rowspan="1" colspan="1">99 (86)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000004</td><td valign="middle" align="center" rowspan="1" colspan="1">11.701</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0001</td><td valign="middle" align="center" rowspan="1" colspan="1">3.034</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">30</td><td valign="middle" align="right" rowspan="1" colspan="1">40 (35)</td><td valign="middle" align="right" rowspan="1" colspan="1">80 (70)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.00005</td><td valign="middle" align="center" rowspan="1" colspan="1">8.314</td><td valign="middle" align="right" rowspan="1" colspan="1">92 (80)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000005</td><td valign="middle" align="center" rowspan="1" colspan="1">10.808</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0004</td><td valign="middle" align="center" rowspan="1" colspan="1">2.494</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">36</td><td valign="middle" align="right" rowspan="1" colspan="1">36 (31)</td><td valign="middle" align="right" rowspan="1" colspan="1">77 (67)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000035</td><td valign="middle" align="center" rowspan="1" colspan="1">8.313</td><td valign="middle" align="right" rowspan="1" colspan="1">85 (74)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000006</td><td valign="middle" align="center" rowspan="1" colspan="1">9.935</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0042</td><td valign="middle" align="center" rowspan="1" colspan="1">1.622</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">42</td><td valign="middle" align="right" rowspan="1" colspan="1">34 (30)</td><td valign="middle" align="right" rowspan="1" colspan="1">72 (63)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000045</td><td valign="middle" align="center" rowspan="1" colspan="1">7.519</td><td valign="middle" align="right" rowspan="1" colspan="1">78 (68)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000007</td><td valign="middle" align="center" rowspan="1" colspan="1">8.706</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0137</td><td valign="middle" align="center" rowspan="1" colspan="1">1.187</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">48</td><td valign="middle" align="right" rowspan="1" colspan="1">33 (29)</td><td valign="middle" align="right" rowspan="1" colspan="1">68 (59)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000051</td><td valign="middle" align="center" rowspan="1" colspan="1">7.016</td><td valign="middle" align="right" rowspan="1" colspan="1">71 (62)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000008</td><td valign="middle" align="center" rowspan="1" colspan="1">7.406</td><td valign="middle" align="center" rowspan="1" colspan="1">0.083</td><td valign="middle" align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">54</td><td valign="middle" align="right" rowspan="1" colspan="1">31 (27)</td><td valign="middle" align="right" rowspan="1" colspan="1">61 (53)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000041</td><td valign="middle" align="center" rowspan="1" colspan="1">5.801</td><td valign="middle" align="right" rowspan="1" colspan="1">65 (57)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000009</td><td valign="middle" align="center" rowspan="1" colspan="1">6.574</td><td valign="middle" align="center" rowspan="1" colspan="1">0.045</td><td valign="middle" align="center" rowspan="1" colspan="1">0.773</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">60</td><td valign="middle" align="right" rowspan="1" colspan="1">28 (24)</td><td valign="middle" align="right" rowspan="1" colspan="1">58 (50)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000062</td><td valign="middle" align="center" rowspan="1" colspan="1">5.833</td><td valign="middle" align="right" rowspan="1" colspan="1">59 (51)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.00006</td><td valign="middle" align="center" rowspan="1" colspan="1">6.028</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0833</td><td valign="middle" align="center" rowspan="1" colspan="1">0.194</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">66</td><td valign="middle" align="right" rowspan="1" colspan="1">25 (22)</td><td valign="middle" align="right" rowspan="1" colspan="1">49 (43)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000058</td><td valign="middle" align="center" rowspan="1" colspan="1">4.742</td><td valign="middle" align="right" rowspan="1" colspan="1">51 (44)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000054</td><td valign="middle" align="center" rowspan="1" colspan="1">5.335</td><td valign="middle" align="center" rowspan="1" colspan="1">0.1582</td><td valign="middle" align="center" rowspan="1" colspan="1">0.593</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">72</td><td valign="middle" align="right" rowspan="1" colspan="1">20 (17)</td><td valign="middle" align="right" rowspan="1" colspan="1">41 (36)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000053</td><td valign="middle" align="center" rowspan="1" colspan="1">4.509</td><td valign="middle" align="right" rowspan="1" colspan="1">45 (39)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000049</td><td valign="middle" align="center" rowspan="1" colspan="1">5.329</td><td valign="middle" align="center" rowspan="1" colspan="1">0.045</td><td valign="middle" align="center" rowspan="1" colspan="1">0.82</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">78</td><td valign="middle" align="right" rowspan="1" colspan="1">19 (17)</td><td valign="middle" align="right" rowspan="1" colspan="1">35 (30)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000036</td><td valign="middle" align="center" rowspan="1" colspan="1">3.556</td><td valign="middle" align="right" rowspan="1" colspan="1">44 (38)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000033</td><td valign="middle" align="center" rowspan="1" colspan="1">5.438</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0024</td><td valign="middle" align="center" rowspan="1" colspan="1">1.882</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">84</td><td valign="middle" align="right" rowspan="1" colspan="1">18 (16)</td><td valign="middle" align="right" rowspan="1" colspan="1">31 (27)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0002</td><td valign="middle" align="center" rowspan="1" colspan="1">2.996</td><td valign="middle" align="right" rowspan="1" colspan="1">41 (36)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.00003</td><td valign="middle" align="center" rowspan="1" colspan="1">5.136</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0013</td><td valign="middle" align="center" rowspan="1" colspan="1">2.14</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">90</td><td valign="middle" align="right" rowspan="1" colspan="1">15 (13)</td><td valign="middle" align="right" rowspan="1" colspan="1">29 (25)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0001</td><td valign="middle" align="center" rowspan="1" colspan="1">1.163</td><td valign="middle" align="right" rowspan="1" colspan="1">38 (33)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000025</td><td valign="middle" align="center" rowspan="1" colspan="1">5.438</td><td valign="middle" align="center" rowspan="1" colspan="1">0.1582</td><td valign="middle" align="center" rowspan="1" colspan="1">4.185</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-medscimonit-24-1970"><p>EP: after successful completion of treatment. Data were represented as Number (Percentage). N/A &#x02013; not applicable. <italic>p</italic> value for two tailed <italic>t</italic>-tests; <italic>q</italic> value for Turkey <italic>post hoc</italic> test. For statistical analysis, the cancerous condition of the patient was considered as 1 and total cancer free condition of the patient was considered as 0. RECIST guidelines evaluation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>